Interleukin-1-receptor antagonist in type 2 diabetes mellitus

Keyphrases

• Type 2 Diabetes Mellitus (T2DM) 100%
• Interleukin-1 Receptor Antagonist (IL-1Ra) 100%
• Anakinra 100%
• Interleukin-1β 66%
• Insulin 66%
• Type 2 Diabetic Patients 66%
• C-reactive Protein 33%
• Interleukin-6 33%
• Body Mass Index 33%
• Placebo 33%
• Placebo Groups 33%
• Glycemia 33%
• Proinsulin 33%
• Once-daily 33%
• β-cell Function 33%
• ClinicalTrials.gov 33%
• Inflammatory Markers 33%
• B Cells 33%
• Insulin Resistance 33%
• Insulin Sensitivity 33%
• Cell Proliferation 33%
• Serious Adverse Events 33%
• Oral Glucose Tolerance Test 33%
• Glycated Hemoglobin 33%
• Skeletal muscle 33%
• Serum Adiponectin 33%
• Parallel Trials 33%
• Cell Apoptosis 33%
• Intravenous Bolus 33%
• Arginine 33%
• Hyperinsulinemic-euglycemic Clamp 33%
• Gene Regulation 33%
• Pancreatic β-cells 33%
• Glucagon 33%
• High Glucose 33%
• Clamp Study 33%
• Impaired Insulin Secretion 33%
• Glycated Hemoglobin Levels 33%
• Pancreatic Islets 33%
• C-peptide Secretion 33%
• Drug-likeness 33%
• Secretory Phase 33%
• Systemic Inflammation Markers 33%
• Symptomatic Hypoglycemia 33%

Medicine and Dentistry

• Maturity Onset Diabetes of the Young 100%
• Beta Cell 100%
• Interleukin 1 Receptor Blocking Agent 100%
• Anakinra 100%
• Placebo 66%
• Patient with Type 2 Diabetes 66%
• Glycated Hemoglobin 66%
• Insulin 66%
• Glucose 66%
• Gene Expression 33%
• C Reactive Protein 33%
• Programmed Cell Death 33%
• Interleukin 1beta 33%
• Interleukin 6 33%
• Body Mass Index 33%
• Proinsulin 33%
• Hypoglycemia 33%
• Body Weight 33%
• Insulin Sensitivity 33%
• Cell Function 33%
• Insulin Release 33%
• Glycemic 33%
• C-Peptide 33%
• Cell Proliferation 33%
• Oral Glucose Tolerance Test 33%
• Insulin Resistance 33%
• Secretion (Process) 33%
• Adipocytokine 33%
• Group Trial 33%
• Interleukin 1 33%
• Pancreatic Islet 33%
• Arginine 33%
• Glucagon 33%
• Inflammation 33%
• Skeletal Muscle 33%
• Adverse Event 33%